Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entresto in Hemodialysis Patients with Hypertension, CSVD and Cognitive Impairment
ChiCTR2200064602Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sacubitril + valsartan in chronic kidney disease (CKD), hypertension (HTN), Cerebral Small Vessel Disease (CSVD) and 2 more, sponsored by Peking Union Medical College Hospital. Primary endpoint: Blood pressure. Started Oct 2022; status: recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)Cerebral Small Vessel Disease (CSVD)confusionheart failure (HF)
Beyond the preview
Go deeper on ChiCTR2200064602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200064602.